<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Trevi Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/trevi-therapeutics-inc</link>
<description>Latest news and press releases for Trevi Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/trevi-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cd9478dffbe2df11e15c.webp</url>
<title>Trevi Therapeutics Inc</title>
<link>https://6ix.com/company/trevi-therapeutics-inc</link>
</image>
<item>
<title>Trevi Therapeutics to Participate in Upcoming May Events</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-to-participate-in-upcoming-may-events</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-to-participate-in-upcoming-may-events</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May. Trevi Therapeutics Investor a</description>
</item>
<item>
<title>Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-closing-of-dollar173-million-underwritten-offering-and-full-exercise-by-underwriters-of-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-closing-of-dollar173-million-underwritten-offering-and-full-exercise-by-underwriters-of-option-to-purchase-additional-shares</guid>
<pubDate>Mon, 20 Apr 2026 20:05:00 GMT</pubDate>
<description>NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common</description>
</item>
<item>
<title>Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-pricing-of-dollar150-million-underwritten-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-pricing-of-dollar150-million-underwritten-offering-of-common-stock</guid>
<pubDate>Fri, 17 Apr 2026 02:42:00 GMT</pubDate>
<description>NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common</description>
</item>
<item>
<title>Trevi Therapeutics to Participate in Upcoming Events</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-to-participate-in-upcoming-events</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-to-participate-in-upcoming-events</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the</description>
</item>
<item>
<title>Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates </title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary</description>
</item>
<item>
<title>Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-to-report-fourth-quarter-and-year-end-2025-financial-results-and-provide-business-updates-on-march-17-2026-33</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-to-report-fourth-quarter-and-year-end-2025-financial-results-and-provide-business-updates-on-march-17-2026-33</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a</description>
</item>
<item>
<title>Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-completion-of-end-of-phase-2-meeting-with-the-fda-gaining-alignment-for-its-development-program-for-idiopathic-pulmonary-fibrosis-related-chronic-cough</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-completion-of-end-of-phase-2-meeting-with-the-fda-gaining-alignment-for-its-development-program-for-idiopathic-pulmonary-fibrosis-related-chronic-cough</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on</description>
</item>
<item>
<title>Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-oppenheimer-36th-123000713</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-oppenheimer-36th-123000713</guid>
<pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
<description>Fireside chat with management on February 25, 2026, at 9:20 a.m. ETNEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chie</description>
</item>
<item>
<title>Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-publication-data-173000526</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-publication-data-173000526</guid>
<pubDate>Thu, 22 Jan 2026 17:30:00 GMT</pubDate>
<description>Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that the key results from the Phase 2b CORAL trial of oral nalbuphine ER for the treatment of chronic cough in patients with IPF have been published in the Journal of t</description>
</item>
<item>
<title>Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-provides-strategic-updates-123000718</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-provides-strategic-updates-123000718</guid>
<pubDate>Thu, 08 Jan 2026 12:30:00 GMT</pubDate>
<description>Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced strategic updates ahead of its participation in the 15th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, CA, from January 12-14</description>
</item>
<item>
<title>Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-appointment-david-hastings-chief-financial-officer-2025</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-appointment-david-hastings-chief-financial-officer-2025</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growthNEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi</description>
</item>
<item>
<title>Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company</description>
</item>
<item>
<title>Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-report-third-quarter-2025-financial-results-and-provide-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-report-third-quarter-2025-financial-results-and-provide-corporate</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a</description>
</item>
<item>
<title>Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-stifel-2025-healthcare-conference-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-stifel-2025-healthcare-conference-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET NEW HAVEN, Conn., Nov. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq:</description>
</item>
<item>
<title>Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-oral-presentation-and-abstracts-chest-2025-annual</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-oral-presentation-and-abstracts-chest-2025-annual</guid>
<pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
<description>Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the</description>
</item>
<item>
<title>Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-two-posters-phase-2a-river-trial-data-will-be-featured</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-announces-two-posters-phase-2a-river-trial-data-will-be-featured</guid>
<pubDate>Thu, 18 Sep 2025 04:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the</description>
</item>
<item>
<title>Trevi Therapeutics to Participate in Upcoming September Conferences</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-upcoming-september-conferences-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-upcoming-september-conferences-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the</description>
</item>
<item>
<title>Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-reports-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-reports-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million</description>
</item>
<item>
<title>Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-report-second-quarter-2025-financial-results-and-provide-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-report-second-quarter-2025-financial-results-and-provide-corporate</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a</description>
</item>
<item>
<title>Trevi Therapeutics to Participate in Upcoming August Conferences</title>
<link>https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-upcoming-august-conferences-2025-07-29</link>
<guid isPermaLink="true">https://6ix.com/company/trevi-therapeutics-inc/news/trevi-therapeutics-participate-upcoming-august-conferences-2025-07-29</guid>
<pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the</description>
</item>
</channel>
</rss>